Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Low doses of the drug FTY720, also called fingolimod, given  to mice once a day for three days eliminated an infection by a  virus that can cause meningitis, an inflammation of the  membranes surrounding the brain and spinal cord. The findings suggest the drug, which boosted anti-viral  immune responses in the mice, may be useful against viruses  that cause high-level, long-lasting infections in people such  as hepatitis C and HIV, the researchers said. Microbiologist and immunologist John Altman of Emory  University in Atlanta, who led the study, said the researchers  plan to assess the effects of the drug on other viruses  including the monkey version of the AIDS virus. Altman, whose findings were published in the journal  Nature, expressed cautious optimism that the drug might work  against certain chronic viral infections in people. “We think it’s crucial that we do experiments to check it  out,” Altman said in a telephone interview. The drug is generally considered to be an immunosuppressant  that works to restrain the body’s natural defenses. That could be helpful in multiple sclerosis, an autoimmune  disease in which the immune system attacks body parts as if  they were foreign invaders. But one effect of the drug seems to facilitate the immune  response, the researchers said. FTY720 among other things traps  white blood cells — key soldiers in the immune system’s fight  against infections — in the lymph nodes, Altman said. With viral infections, the lymph nodes are where the immune  response can get primed and started, Altman said. Some viruses  replicate themselves at high levels in lymph nodes, including  the human immunodeficiency virus that causes AIDS. They tested the drug against a mouse virus called  lymphocytic choriomeningitis, which causes chronic infections  by escaping immune responses. “In the absence of treatment (with FTY720) we have an  exhausted immune response. In the presence of treatment, we  regain a robust cellular immune response,” Altman said. Swiss drug maker Novartis said in June two multiple  sclerosis patients taking FTY720 in clinical trials had  problems with infections and one died, but the role of the drug  in the cases was unclear. Novartis plans at the end of 2009 to seek approval by the  European Union for FTY720 to treat MS, spokeswoman Valerie Tate  said by e-mail. The drug is currently in late-stage trials. Altman said his study was backed by the U.S. government’s  National Institutes of Health and was not funded by Novartis.
Example Output: MS drug may work against viral infection: study.

Example Input: A still image provided by KPIX TV and taken from the broadcaster's video footage shows Timothy Ray Brown during an interview at his home in San Francisco. Timothy Ray Brown, was a young HIV-positive American living and working in Berlin who had developed leukaemia and suffered a relapse after initial treatment. REUTERS/Courtesy KPIX TV/Handout Dramatic scientific advances since HIV was first discovered 30 years ago this week mean the virus is no longer a death sentence. Thanks to tests that detect HIV early, new antiretroviral AIDS drugs that can control the virus for decades, and a range of ways to stop it being spread, 33.3 million people around the world are learning to live with HIV. People like Vuyiseka Dubula, an HIV-positive AIDS activist and mother in Cape Town, South Africa, can expect relatively normal, full lives. “I’m not thinking about death at all,” she says. “I’m taking my treatment and I’m living my life.”   Nonetheless, on the 30th birthday of HIV, the global scientific community is setting out with renewed vigor to try to kill it. The drive is partly about science, and partly about money. Treating HIV patients with lifelong courses of sophisticated drugs is becoming unaffordable. Caring for HIV patients in developing countries alone already costs around $13 billion a year and that could treble over the next 20 years. In tough economic times, the need to find a cure has become even more urgent, says Francoise Barre Sinoussi, who won a Nobel prize for her work in identifying Human Immunodeficiency Virus (HIV). “We have to think about the long term, including a strategy to find a cure,” she says. “We have to keep on searching until we find one.”   The Berlin patient is proof they could. His case has injected new energy into a field where people for years believed talk of a cure was irresponsible. Timothy Ray Brown was living in Berlin when besides being HIV-positive, he had a relapse of leukemia. He was dying. In 2007, his doctor, Gero Huetter, made a radical suggestion: a bone marrow transplant using cells from a donor with a rare genetic mutation, known as CCR5 delta 32. Scientists had known for a few years that people with this gene mutation had proved resistant to HIV. “We really didn’t know when we started this project what would happen,” Huetter, an oncologist and haematologist who now works at the University of Heidelberg in southern Germany, told Reuters. The treatment could well have finished Brown off. Instead he remains the only human ever to be cured of AIDS. “He has no replicating virus and he isn’t taking any medication. And he will now probably never have any problems with HIV,” says Huetter. Brown has since moved to San Francisco. Most experts say it is inconceivable Brown’s treatment could be a way of curing all patients. The procedure was expensive, complex and risky. To do this in others, exact match donors would have to be found in the tiny proportion of people — most of them of northern European descent — who have the mutation that makes them resistant to the virus. Dr Robert Gallo, of the Institute of Virology at the University of Maryland, puts it bluntly. “It’s not practical and it can kill people,” he said last year. Sinoussi is more expansive. “It’s clearly unrealistic to think that this medically heavy, extremely costly, barely reproducible approach could be replicated and scaled-up ... but from a scientist’s point of view, it has shown at least that a cure is possible,” she says. The International AIDS Society will this month formally add the aim of finding a cure to its HIV strategy of prevention, treatment and care. A group of scientist-activists is also launching a global working group to draw up a scientific plan of attack and persuade governments and research institutions to commit more funds. Money is starting to flow. The U.S. National Institutes of Health is asking for proposals for an $8.5 million collaborative research grant to search for a cure, and the Foundation for AIDS Research, or amfAR, has just announced its first round of four grants to research groups “to develop strategies for eradicating HIV infection.”   Until recently, people in HIV and AIDS circles feared that to direct funds toward the search for a cure risked detracting from the fight to get HIV-positive people treated. Even today, only just over five million of the 12 million or so people who need the drugs actually get them. HIV first surfaced in 1981, when scientists at the U.S. Centers for Disease Control and Prevention discovered it was the cause of acquired immunodeficiency syndrome (AIDS). An article in the CDC’s Morbidity and Mortality Weekly Report of that June referred to “five young men, all active homosexuals” from Los Angeles as the first documented cases. “That was the summer of ‘81. For the world it was the beginning of the era of HIV/AIDS, even though we didn’t know it was HIV then,” says Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, who has made AIDS research his life’s work. In the subsequent three decades, the disease ignorantly branded “the gay plague” has become one of the most vicious pandemics in human history. Transmitted in semen, blood and breast milk, HIV has devastated poorer regions, particularly sub-Saharan Africa, where the vast majority of HIV-positive people live. As more tests and treatment have become available, the number of new infections has been falling. But for every two with HIV who get a chance to start on AIDS drugs, five more join the “newly infected” list. United Nations data show that despite an array of potential prevention measures — from male circumcision to sophisticated vaginal or anal microbicide gels — more than 7,100 new people catch the virus every day. Treatment costs per patient can range from around $150 a year in poor countries, where drugs are available as cheap generics, to more than $20,000 a year in the United States. The overall sums are huge. A recent study as part of a non-governmental campaign called AIDS2031 suggests that low and middle-income countries will need $35 billion a year to properly address the pandemic by 2031. That’s almost three times the current level of around $13 billion a year. Add in the costs of treatment in rich countries and experts estimate the costs of HIV 20 years from now will reach $50 to $60 billion a year. “It’s clear that we have to look at another possible way of managing of the epidemic beyond just treating everyone forever,” says Sharon Lewin, a leading HIV doctor and researcher from Monash University in Melbourne, Australia. In some ways, we have been here before. Early AIDS drugs such as AZT came to market in the late 1980s, but within a decade they were overtaken by powerful cocktail treatments known as HAART, or highly active antiretroviral treatment. HAART had a dramatic effect — rapidly driving the virus out of patients’ blood and prompting some to say a cure was just around the corner. But then scientists discovered HIV could lie low in pools or reservoirs of latent infection that even powerful drugs could not reach. Talk of a cure all but died out. “Scientifically we had no means to say we were on the way to finding a cure,” says Bertrand Audoin, executive director of the Geneva-based International AIDS Society. “Scientists ... don’t want to make any more false promises. They didn’t want to talk about a cure again because it really wasn’t anywhere on the horizon.”   The ultimate goal would allow patients to stop taking AIDS drugs, knocking a hole in a $12 billion-a-year market dominated by Californian drugmaker Gilead and the likes of Pfizer, GlaxoSmithKline and Merck. It’s unlikely to happen anytime soon, but Brown’s case has opened the door to new ideas. “What it proved was that if you make someone’s cells resistant to HIV...then all the last bits of HIV, that hang around for a long time in patients on treatment, did in fact decay and disappear,” says Lewin. Now scientists working on mimicking the effect of the Berlin patient’s transplant have had some success. One experimental technique uses gene therapy to take out certain cells, make them resistant to HIV and then put them back into patients in the hope they will survive and spread. At an HIV conference in Boston earlier this year, American researchers presented data on six patients who had large numbers of white blood cells known as CD4 cells removed, manipulated to knock out the existing CCR5 gene, and then replaced. “It works like scissors and cuts a piece of genetic information out of the DNA, and then closes the gap,” says Huetter. “Then every cell arising from this mother cell has this same mutation.”   Early results showed the mutated cells managed to survive inside the bodies of the patients at low levels, remaining present for more than three months in five. “This was a proof of concept,” says Lewin. Another potential avenue is a small group of patients known as “elite controllers”, who despite being infected with HIV are able to keep it under control simply with their own immune systems. Researchers hope these patients could one day be the clue to developing a successful HIV/AIDS vaccine or functional cure. Scientists are also exploring ways to “wake up” HIV cells and kill them. As discovered in the late 1990s, HIV has a way of getting deep into the immune system itself — into what are known as resting memory T-cells — and going to sleep there. Hidden away, it effectively avoids drugs and the body’s own immune response. “Once it goes to sleep in a cell it can stay there forever, which is really the main reason why we can’t cure HIV with current drugs,” says Lewin. Her team in Melbourne and another group in the United States are about to start the first human trials using a drug called SAHA or vorinostat, made by Merck and currently used in cancer treatment, which has shown promise in being able to wake up dormant HIV. As scientists begin to talk up a cure, the old question of whether that’s the right goal has re-emerged. Seth Berkley, a medical epidemiologist and head of the U.S.-based International AIDS Vaccine Initiative (IAVI) is concerned. An HIV-positive person holds a placard during a programme organized to mark World AIDS Day in Kathmandu December 1, 2010. To match Special Report AIDS/ REUTERS/Deepa Shrestha “From a science point of view, it’s a fabulous thing to do. It’s a great target and a lot of science will be learned. But from a public health point of view, the primary thing you need to do is stop the flow of new infections,” says Berkley. “We need a prevention revolution. That is absolutely critical.”   Vuyiseka Dubula agrees. The South African activist finds talk of a cure for HIV distracting, almost disconcerting. “This research might not yield results soon, and even when it does, access to that cure is still going to be a big issue,” she says. “So in the meantime, while we don’t have the answer on whether HIV can be cured or not, we need to save lives.”
Example Output: Special Report: An end to AIDS?.

Example Input: By the time Trump landed back at Joint Base Andrews outside Washington a few hours later, the plan was off. And its future is unclear. For nearly two months, momentum had been building inside the White House to try to halt a youth vaping epidemic that experts feared was hurting as many as 5 million teenagers. Both first lady Melania Trump and Ivanka Trump, the president’s daughter and senior adviser, pushed for the ban, which was also being championed internally by White House counselor Kellyanne Conway, who has taken the lead on some public health issues. But as Trump sat surrounded by political advisers on the flights to and from Lexington, he grew reluctant to sign the ban, convinced it could alienate voters who would be financially or otherwise affected by a vaping ban, according to two White House and campaign officials not authorized to speak publicly about private conversations. A news conference scheduled by Health and Human Services Secretary Alex Azar to announce the ban was canceled, while more meetings with industry leaders and lobbyists were proposed, according to the officials. Trump tweeted last week that he’ll be meeting with vaping industry representatives, medical professionals and others “to come up with an acceptable solution to the Vaping and E-cigarette dilemma.” The White House has yet to announce a date for a meeting. This month, Trump campaign manager Brad Parscale and others showed the president polling data indicating that e-cigarette users could abandon him if he followed through with the ban, the officials said. Campaign aides also highlighted an aggressive social media campaign — #IVapeIVote — in which advocates claimed a ban would force the closure of vaping shops, eliminating jobs and sending users of electronic cigarettes back to traditional smokes. Parscale also pointed out the risk that a ban could have on e-cigarette users in key battleground states that Trump narrowly won in 2016. Others in the West Wing, including Conway, have argued that a ban could be a winning issue with suburban voters, including mothers, who have fled the president in large numbers. Few would predict where Trump, who is known to abruptly change his mind, would end up since he recently has been consumed with other matters, notably televised impeachments hearings. The vaping industry’s largest trade group said Monday the administration was heading “in the right direction for adult smokers and their families.” “Bans don’t work, they never have,” Tony Abboud, executive director of the Vapor Technology Association, said in a statement. Gregory Conley, president of the American Vaping Association, an advocacy organization, added that the government should put in place “sensible and targeted regulations” before it resorts to prohibition, which opponents of a ban said could lead to the creation of an underground market for e-cigarettes. But Matt Myers, president of the Campaign for Tobacco-Free Kids, said Trump would be guilty of “terrible public policy” and “bad politics” if he backs down. “This is one of the very few issues on which public views are unified,” Myers said in a telephone interview. “There are a small number of vape shop owners who are loud and don’t care. But there are millions more moms and dads who are deeply concerned.” Robin Koval, president and CEO of the Truth Initiative, a nonprofit, anti-tobacco organization, called on Trump to implement the original plan. “The health of America’s youth must come first and is not for sale or political gain,” Koval said in a statement. The first lady opened the White House to a group of young people from the Truth Initiative in October to tell her about their experiences with vaping. Trump’s initial pledge Sept. 11 to ban virtually all flavored e-cigarettes stunned vaping proponents and was immediately embraced by anti-tobacco advocates. In an Oval Office appearance with the first lady and Azar, Trump said the government would act within weeks to protect children from fruit, candy, dessert and other sweet vaping flavors, including mint and menthol. The announcement followed a tweet two days earlier by Mrs. Trump expressing concern “about the growing epidemic of e-cigarette use in our children.” “We need to do all we can to protect the public from tobacco-related disease and death, and prevent e-cigarettes from becoming an on-ramp to nicotine addiction for a generation of youth,” she said. But within days, Trump tweeted that e-cigarettes might be a less-harmful alternative for smokers, a point long made by the industry. Meanwhile, vaping lobbyists, conservative groups and Republican lawmakers from key states warned Trump that a crackdown could cost him with voters. The Vapor Technology Association launched ads and an online campaign promising to punish Trump and other politicians who support vaping restrictions. Conservative groups that have long promoted vaping as an alternative to smoking, including Grover Norquist’s Americans for Tax Reform, joined the criticism. That group and others helped organize protests against banning flavors, including one outside the White House. Trump supporters also showed up at some of his campaign rallies holding signs expressing their opposition to a ban. The industry warned some 15,000 to 19,000 vaping shops across the country - and jobs - could be wiped out if flavors were eliminated. The administration was widely expected earlier this month to announce a scaled-back flavor ban that would exempt menthol, citing research that the flavor was not widely used by children. But no decision came. Trump instead told reporters on Nov. 8 — four days after his political advisers buttonholed him on the Kentucky trip — he was considering new approaches to curbing teen use, including raising the minimum age for purchasing tobacco from 18 to 21. Last week, Wisconsin Republican Sen. Ron Johnson sent Trump a letter warning against “unchecked government action that stifles innovation and restricts adults’ freedom to choose safer alternatives to smoking.” Asked how disappointed the first lady would be if the president did not follow through with a ban, her spokeswoman, Stephanie Grisham, who also speaks for the president, said Mrs. Trump’s priority is the health and safety of children. “She does not believe e-cigarettes or any nicotine products should be marketed or available to children,” Grisham said. Underage vaping has reached what health officials call epidemic levels. In the latest government survey, 1 in 4 high school students reported using e-cigarettes in the previous month. Anticipating a ban on flavors, Juul Labs, the nation’s largest e-cigarette maker, said this month it would stop selling its best-selling, mint-flavored nicotine pods. ___ Lemire reported from New York.
Example Output:
Trump backing off banning vaping flavors popular with teens.